Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jian-Cheng Li

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 30, 2013
Ultra-performance liquid chromatography-tandem mass spectrometry determination and depletion profile of flunixin residues in tissues after single oral administration in rabbitsAi-Ling Zhu, Tao Peng, Liang Liu, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2011
Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine coreRobert L Dow, Melissa Andrews, Gary E Aspnes, et al.
Molecular Medicine (Cambridge, Mass.)|September 18, 2020
Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy optionsLong Huang, Xiao-Liu Jiang, Hong-Bin Liang, et al.
Journal of the American Chemical Society|April 26, 2022
<i>In Vitro</i> Reconstitution of Cinnamoyl Moiety Reveals Two Distinct Cyclases for Benzene Ring FormationJing Shi, Yang Shi, Jian Cheng Li, et al.
Bioorganic & Medicinal Chemistry|July 23, 2013
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitorRobert L Dow, Melissa P Andrews, Jian-Cheng Li, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2009
Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activityDaniel P Walker, Michael P Zawistoski, Molly A McGlynn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 16, 2014
Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancerYong Bao, Fang Peng, Qi-Chao Zhou, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1Robert L Dow, Jian-Cheng Li, Michael P Pence, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicityKevin J Filipski, Jianwei Bian, David C Ebner, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitusJeffrey A Pfefferkorn, Meihua Tu, Kevin J Filipski, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 30, 2013
Ultra-performance liquid chromatography-tandem mass spectrometry determination and depletion profile of flunixin residues in tissues after single oral administration in rabbitsAi-Ling Zhu, Tao Peng, Liang Liu, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2011
Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine coreRobert L Dow, Melissa Andrews, Gary E Aspnes, et al.
Molecular Medicine (Cambridge, Mass.)|September 18, 2020
Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy optionsLong Huang, Xiao-Liu Jiang, Hong-Bin Liang, et al.
Journal of the American Chemical Society|April 26, 2022
<i>In Vitro</i> Reconstitution of Cinnamoyl Moiety Reveals Two Distinct Cyclases for Benzene Ring FormationJing Shi, Yang Shi, Jian Cheng Li, et al.
Bioorganic & Medicinal Chemistry|July 23, 2013
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitorRobert L Dow, Melissa P Andrews, Jian-Cheng Li, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2009
Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activityDaniel P Walker, Michael P Zawistoski, Molly A McGlynn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 16, 2014
Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancerYong Bao, Fang Peng, Qi-Chao Zhou, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1Robert L Dow, Jian-Cheng Li, Michael P Pence, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicityKevin J Filipski, Jianwei Bian, David C Ebner, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitusJeffrey A Pfefferkorn, Meihua Tu, Kevin J Filipski, et al.
Pageof 5